# Tongmai Jiangtang Capsule for Cardiovascular Clinical Outcomes in High-Risk Metabolic Syndrome Patients

> **NCT06908473** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Guangdong Provincial Hospital of Traditional Chinese Medicine** · enrollment: 530 (estimated)

## Conditions studied

- Metabolic Syndrome
- Cardiovascular Disease (CKD)
- Cerebrovascular Disease
- Qi Deficiency and Blood Stasis

## Interventions

- **DRUG:** Participants will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment.
- **DRUG:** A placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC

## Key facts

- **NCT ID:** NCT06908473
- **Lead sponsor:** Guangdong Provincial Hospital of Traditional Chinese Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-04-24
- **Primary completion:** 2028-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 530 (ESTIMATED)
- **Last updated:** 2025-06-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06908473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06908473, "Tongmai Jiangtang Capsule for Cardiovascular Clinical Outcomes in High-Risk Metabolic Syndrome Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06908473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*